Platelet cyclic nucleotide phosphodiesterase (Platelet PDE)

Platelet cyclic nucleotide phosphodiesterases, primarily comprising the isoenzymes PDE2A, PDE3A, and PDE5A, are critical enzymes that regulate the intracellular concentrations of cAMP and cGMP in platelets (Gresele et al., 2011, PMID: 21834855). PDE3A is the dominant cAMP-hydrolyzing enzyme in platelets, and its inhibition leads to elevated cAMP levels, which activate protein kinase A (PKA) to suppress platelet activation and aggregation (Haslam et al., 1999). PDE5A specifically degrades cGMP, and its inhibition enhances the nitric oxide-cGMP pathway, activating protein kinase G (PKG) to further inhibit platelet function and promote vasodilation (StatPearls, 2023). PDE2A is a dual-substrate enzyme that can be stimulated by cGMP to increase cAMP hydrolysis, acting as a regulatory link between the two signaling pathways (PubMed: 19079318). These enzymes are major therapeutic targets for antiplatelet therapy in conditions such as peripheral arterial disease and stroke prevention. Drugs like cilostazol and dipyridamole exert their clinical effects by inhibiting these PDEs, although systemic inhibition can lead to side effects such as headache and hypotension (StatPearls, 2023).

Other names

Phosphodiesterase isoenzymes regulating platelet cAMP/cGMPPDE2APDE3APDE5APlatelet phosphodiesterases

Inhibition of phosphodiesterase enzymes (primarily PDE3A and PDE5A) to increase intracellular cAMP and cGMP levels, which activates protein kinases that inhibit platelet activation and aggregation.